Last reviewed · How we verify
KAN-101 (kan-101)
At a glance
| Generic name | kan-101 |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | Phase 2 |
Approved indications
Common side effects
- Nausea
- Abdominal pain
- Diarrhoea
- Vomiting
- Fatigue
- Abdominal distension
- Headache
- Abdominal pain upper
- Vertigo
- Dyspepsia
- Gastrointestinal sounds abnormal
- Dizziness
Key clinical trials
- A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it) (PHASE1, PHASE2)
- A Study of Efficacy, Safety, and Tolerability of KAN-101 in People With Celiac Disease (PHASE2)
- Assessment of KAN-101 in Celiac Disease (ACeD) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KAN-101 CI brief — competitive landscape report
- KAN-101 updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI